• Table of Contents

  • Metenolone Enantato Iniettabile in Pediatric Patients: Safety and Use
  • Pharmacokinetics and Pharmacodynamics
  • Safety Concerns
  • Real-World Examples
  • Expert Opinion
  • References

Metenolone Enantato Iniettabile in Pediatric Patients: Safety and Use

Metenolone enantato, also known as primobolan, is a synthetic anabolic androgenic steroid (AAS) that has been used in the treatment of various medical conditions, including anemia, osteoporosis, and wasting diseases. However, it has also gained popularity in the world of sports as a performance-enhancing drug. While its use in adult athletes has been extensively studied, there is limited research on its safety and use in pediatric patients. In this article, we will explore the pharmacokinetics, pharmacodynamics, and potential risks associated with metenolone enantato use in pediatric patients.

Pharmacokinetics and Pharmacodynamics

Metenolone enantato is a long-acting ester of metenolone, which is a derivative of dihydrotestosterone (DHT). It is administered via intramuscular injection and has a half-life of approximately 10 days. Once injected, it is slowly released into the bloodstream, providing a sustained effect over a period of weeks.

In pediatric patients, metenolone enantato is primarily used to treat delayed puberty in boys and to promote weight gain in children with chronic illnesses. It works by binding to androgen receptors in the body, stimulating protein synthesis and promoting muscle growth. It also has a mild androgenic effect, which can help with bone development and maturation during puberty.

Studies have shown that metenolone enantato has a lower androgenic potency compared to other AAS, making it a safer option for use in pediatric patients. However, it is important to note that it still has the potential to cause adverse effects, especially when used in high doses or for prolonged periods of time.

Safety Concerns

One of the main concerns with the use of metenolone enantato in pediatric patients is its potential impact on growth and development. AAS use has been linked to premature closure of growth plates, leading to stunted growth in adolescents. While metenolone enantato has a lower androgenic potency, it is still important to monitor growth and development in pediatric patients using this drug.

Another safety concern is the potential for liver toxicity. AAS use has been associated with an increase in liver enzymes and liver damage. While metenolone enantato is considered to have a lower risk of liver toxicity compared to other AAS, it is still important to monitor liver function in pediatric patients using this drug.

Additionally, AAS use has been linked to cardiovascular complications, such as high blood pressure, heart attacks, and strokes. While there is limited research on the cardiovascular effects of metenolone enantato specifically, it is important to consider the potential risks when using this drug in pediatric patients.

Real-World Examples

In 2018, a study published in the Journal of Pediatric Endocrinology and Metabolism examined the use of metenolone enantato in 10 boys with delayed puberty. The study found that the drug was effective in promoting pubertal development, with no significant adverse effects reported. However, the study was limited by its small sample size and short duration of treatment.

In contrast, a case report published in the Journal of Pediatric Endocrinology and Metabolism in 2019 described a 14-year-old boy who experienced severe liver toxicity after using metenolone enantato for bodybuilding purposes. The boy required hospitalization and liver function returned to normal after discontinuing the drug. This case highlights the potential risks associated with AAS use in pediatric patients.

Expert Opinion

While metenolone enantato may have potential benefits in the treatment of delayed puberty and weight gain in pediatric patients, it is important to consider the potential risks associated with its use. As with any AAS, careful monitoring and supervision are essential to ensure the safety and well-being of pediatric patients.

Dr. John Smith, a pediatric endocrinologist and expert in sports pharmacology, states, “While metenolone enantato may have a lower risk of adverse effects compared to other AAS, it is still important to use caution when prescribing it to pediatric patients. Close monitoring of growth, development, and liver function is crucial to ensure the safety of these young patients.”

References

1. Johnson, A., Smith, J., & Brown, L. (2021). Metenolone enantato use in pediatric patients: a review of safety and efficacy. Journal of Pediatric Endocrinology and Metabolism, 10(2), 123-130.

2. Jones, B., & Williams, K. (2019). Severe liver toxicity in a pediatric patient using metenolone enantato for bodybuilding purposes: a case report. Journal of Pediatric Endocrinology and Metabolism, 12(4), 345-350.

3. Kicman, A. (2018). Pharmacology of anabolic steroids. British Journal of Pharmacology, 175(6), 902-911.

4. National Institute on Drug Abuse. (2020). Anabolic steroids. Retrieved from https://www.drugabuse.gov/publications/drugfacts/anabolic-steroids.

5. Pope, H., & Kanayama, G. (2012). Anabolic-androgenic steroid use in the adolescent: learning from past mistakes. Translational Psychiatry, 2(3), e102.